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Abstract
Background: As transcatheter aortic valve replacement (TAVR) procedures in-
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crease, more data is available on the development of conduction abnormalities
requiring permanent pacemaker (PPM) implantation post‐TAVR. Mechanistically,
new pacemaker implantation and incidence of associated tricuspid regurgitation
(TR) post‐TAVR is not well understood. Studies have evaluated the predictability of
patient anatomy towards risk for needing permanent pacemaker (PPM) post‐TAVR;
however, little has been reported on new PPM and TR in patients post‐TAVR.
Methods: This retrospective study identified patients at our health system who
underwent PPM following TAVR from January 2014 to June 2018. Data from both
TAVR and PPM procedures as well as patient demographics were collected. Echocardiographic data before TAVR, between TAVR and PPM placement, and the most
recent echocardiogram at the time of chart review were analyzed.
Results: Of 796 patients who underwent TAVR between January 2014 and June
2018, 89 patients (11%) subsequently required PPM. Out of the 89 patients who
required PPM implantation, 82 patients had pre‐TAVR and 2‐year post‐TAVR
echocardiographic imaging data. At baseline, 22% (18/82) of patients had at least
moderate TR. At 2‐year post‐TAVR echocardiographic imaging follow‐up; 27% (22/
82) of patients had at least moderate TR. Subgroup analysis was performed according to the TAVR valve size implanted. In patients who received a TAVR device < 29 mm in diameter in size, 25% (11/44) had worsening TR. In patients who
received a TAVR device ≥ 29 mm in diameter, 37% (14/38) had worsening TR.
Conclusion: We have demonstrated a patient population that may be predisposed
to developing worsening TR and right heart function after TAVR and Pacemaker
implantation.
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| INTRODUCTION
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post‐TAVR echocardiographic imaging follow‐up, 27% (22/82) of
patients had at least moderate tricuspid regurgitation.

Transcatheter aortic valve replacement (TAVR) for severe sympto-

Subgroup analysis of the rate of tricuspid regurgitation was

matic aortic stenosis has been studied extensively in the high, in-

performed according to TAVR valve size implanted. In the population

termediate, and low surgical risk patient populations. The need for

receiving a TAVR device < 29 mm in diameter in size, follow‐up

new permanent pacemaker (PPM) implantation post‐TAVR is a re-

echocardiographic data were available in 44 out of the 47 patients. In

cognized potential complication, through multiple pathways asso-

the population who received a TAVR device ≥ 29 mm in diameter in

ciated with injury to the intrinsic cardiac conduction system during

size, follow‐up echocardiographic information was available in 38 out

device deployment.1–4 New PPM requirements post‐TAVR have

of the 42 patients. On 2‐year follow‐up imaging, a comparison was

been reported with rates between 17.8% and 35%.1,5–7 Additionally,

made between TAVR device < 29 mm and TAVR device ≥ 29 mm in

new conduction abnormalities requiring PPM are more common

regard to change in TR score (Table 1). If the TR score pre‐TAVR

following TAVR than SAVR.8,9 Studies have evaluated the predict-

matched or was followed by a lower TR score 2‐year post‐TAVR,

ability of patient‐anatomy toward risk for PPM post‐TAVR; however,

then this was considered a TR Score Difference of 0. If the TR score

little has been reported on the incidence and degree of TR after new

pre‐TAVR was 1 and the TR score 2‐year post‐TAVR was 2, then this

PPM placement in patients who underwent TAVR.

would be a TR Score Difference of 1 (Table 6). On 2‐year follow‐up
imaging, in patients who received a TAVR device < 29 mm in size,
25% (11/44) were found to have a TR Score Difference of 1 or

2

| METHODS

greater. Of these 11 smaller device sized patients, 3 were implanted
with a self‐expanding valve, and the remaining 8 patients were im-

This retrospective study identified patients at our academic health

planted with a balloon‐expandable valve. On 2‐year follow‐up ima-

system who underwent PPM following TAVR from January 2014 to

ging, patients who received a TAVR device ≥ 29 mm in diameter, 37%

June 2018. The Institutional Review Board reviewed and approved

(14/38) were found to have a TR Score Difference of 1 or greater. Of

this study. Data from both TAVR and PPM procedures as well as

these 14 larger device sized patients, 3 were implanted with a self‐

patient demographics were collected. Echocardiographic data before

expanding valve, and the remaining 11 patients were implanted with

TAVR, between TAVR and PPM placement, and the most recent

a balloon‐expandable valve.

echocardiogram at the time of chart review were obtained. Data

Beyond tricuspid regurgitation grading, additional right heart

points collected included ejection fraction (EF), degree of tricuspid

echocardiographic parameters were evaluated for secondary effects

regurgitation (based on a numerical scale seen in Table 1), tricuspid

of tricuspid regurgitation (Tables 3–5). There was a statistically sig-

annular plane systolic excursion (TAPSE), degree of inferior vena

nificant decrease in right ventricular systolic pressure (p = .010) in

cava (IVC) dilation, right ventricular basal diameter (RVD), right

the full set of study patients (Table 3). In patients who received a

ventricle systolic pressure (RVSP), and right atrium (RA) area.

TAVR device < 29 mm in diameter, there were no statistically sig-

Change in outcome variables was analyzed using the paired

nificant changes in secondary right heart echocardiographic para-

t‐test in the presence of distributional normality and the Wilcoxon

meters (Table 4). In patients who received a TAVR device ≥ 29 mm in

signed‐rank test in the absence of distributional normality. Con-

size, there was a trend toward an increase in RV basal diameter size,

tinuous variables were described as means and standard deviations.

Tricuspid Regurgitation Score, and RA area that did not reach sta-

Categorical data were described with frequencies and percentages.

tistical significance (Table 3). In this larger device group, there was a

p < .05 was considered statistically significant.

statistically significant decrease in measured right ventricular systolic pressure (p = .024; Table 5).

3

| RESULTS

Out of the 796 patients who underwent TAVR between January

TABLE 1

Tricuspid regurgitation scale

implantation (Figure 1). Of these 89 study patients, the majority

Tricuspid
Regurgitation Score

Tricuspid Regurgitation Severity
Definition

were Caucasian (87%), Male gender (60%), with a mean age of

0

No tricuspid regurgitation

79.6 ± 8.7 years (Table 2). Twenty‐four patients (27%) received a

1

Trivial tricuspid regurgitation

2

Mild tricuspid regurgitation

3

Mild‐moderate tricuspid regurgitation

Out of the 89 patients who received a PPM implantation, 82

4

Moderate tricuspid regurgitation

patients had pre‐TAVR and 2‐year post‐TAVR echocardiographic

5

Moderate‐severe tricuspid regurgitation

6

Severe tricuspid regurgitation

2014 and June 2018, 89 patients (11%) subsequently required PPM

self‐expanding TAVR device (Medtronic, Minneapolis, MN) and 65
patients (73%) received a balloon‐expandable valve (Edwards Lifesciences, Irvine, CA).

imaging data available for review. At baseline, 22% (18/82) of patients had at least moderate tricuspid regurgitation. At 2‐year
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F I G U R E 1 Patient stratification. PPM,
permanent pacemaker; TAVR, transcatheter
aortic valve replacement
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| DI SCUSSION

our patient population who received a TAVR device size greater than
or equal to 29 mm in size and a post‐TAVR PPM, there was an ad-

This study is the first to offer long‐term follow‐up insight into the

ditional trend toward early signs of right‐sided structural heart dis-

hemodynamic context of TR following new PPM implantation im-

ease as evidenced by an increase in RVD (Δ = 0.4 cm, p = .220) and a

mediately post‐TAVR. Novel to this study, there was a signal

statistically significant decrease in RVSP (Δ = 7.2 mmHg, p = .024) at

between the size of TAVR device implanted and the risk of pro-

2‐year follow‐up.

gression of severity of baseline TR. On 2‐year follow‐up imaging

Anatomically, device size associated rate of PPM implantation and

studies, patients who received TAVR devices larger than or equal to

TR severity could be secondary to the proximity of the aortic annulus

diameters of 29 mm in size, with a PPM, were noted to have a TR

right and non‐coronary cusps to the location of the cardiac conduction

score difference of 1 or greater in 12% more patients than those who

system; triangle of Koch.10 The triangle of Koch is located posterior to

received smaller devices (Table 6) with a pacemaker. Of note, this

the right and noncoronary cusps of the aortic annulus. Native aortic

observation was made in the subgroup of patients who had some

annuli are elliptical in shape, post‐TAVR implantation, the native aortic

degree of underlying tricuspid regurgitation present pre‐TAVR. In

annuli become circular. Deformation of the tricuspid commissure by the
smoothing of the aortic annulus causes increased pressure on the
triangle of Koch. Larger TAVR valves and over‐sizing during valve an-

TABLE 2

Patient demographics

Age at TAVR

choring can also result in tricuspid annular deformation and increased
79.6 years (±8.7 years)

malcoaptation of tricuspid leaflet coaptation. This changes the septal:anterolateral and septal:posterolateral diameter of the tricuspid

Sex
Male

53 (60%)

commissures resulting in the annulus being more prone to TR due to

Female

36 (40%)

alteration of the shape of the septal wall of tricuspid annulus and
anteroseptal commissure. Additionally, if a pacer wire is implanted,

Race
White

78 (87%)

African American

9 (10%)

Other

2 (2%)

Body mass index

31.0 kg/m2 (±14.0 kg/m2)

Comorbidities

deformation of the tricuspid anteroseptal commissure may anatomically
shift pacer leads to migrate from commissure implantation to increased
contact with the body of the septal leaflet. Our results suggest an
increased incidence of TR with a larger valve size ≥ 29 mm in diameter after PPM post‐TAVR.
Other mechanisms for pacemaker induced tricuspid regurgita-

Atrial fibrillation

43 (48%)

tion have been reported.11–14 PPM mechanisms of TR may be sec-

COPD

20 (22%)

ondary to pacemaker leads causing tethering of the septal

Diabetes

35 (39%)

leaflet along the tricuspid annulus thereby impairing leaflet coapta-

Hypertension

66 (74%)

Chronic kidney disease

36 (40%)

Type of valve placed during TAVR

tion and closure, lead entanglement, lead adherence, and less commonly leaflet perforation.12,15 Additionally, asynchronous right
ventricle (RV) pacing from abnormal RV activation from the PPM

Balloon‐expandable

65 (73%)

may manifest later in time as biventricular heart failure with RV

Self‐expandable

24 (27%)

cavitary dilatation and clinically significant TR.15 Pre‐existing clini-

Abbreviations: COPD, chronic obstructive pulmonary disease; TAVR,
transcatheter aortic valve replacement.

cally significant TR has additionally been identified as a predictor for
the need of PPM post‐TAVR.16
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Variable

Baseline
echo
pre‐TAVR

Echocardiogram
after pacemaker
placement

Difference in
echocardiographic
data

p

EF (%)

53.8 ± 13.8

52.6 ± 14.3

−1.2 ± 11.7

.393 (W)

Tricuspid Regurgitation Score

2.5 ± 1.5

2.5 ± 1.3

0.0 ± 1.2

.926 (T)

TAPSE (cm)

2.0 ± 0.4

2.0 ± 0.4

0.0 ± 0.4

.983 (T)

IVC dilation (cm)

2.3 ± 0.5

2.3 ± 0.5

0.0 ± 0.6

1.000 (W)

RVD (cm)

3.2 ± 0.9

3.4 ± 0.8

0.1 ± 1.0

.467 (T)

RVSP (mmHg)

38.7 ± 12.4

33.9 ± 14.5

−4.7 ± 14.2

.010 (T)

RA area (cm2)

16.2 ± 7.8

17.6 ± 7.9

1.3 ± 7.2

.534 (T)

ET AL.

T A B L E 3 Echocardiographic changes
from before TAVR to 2 years after
Permanent Pacemaker implantation

Abbreviations: EF, ejection fraction; IVC, inferior vena cava; RA, right atrium; RVD, right ventricular
diameter; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion;
TAVR, transcatheter aortic valve replacement; (T), paired t‐test; (W), Wilcoxon signed‐rank test.

Variables

Baseline
echo
pre‐TAVR

Echocardiogram
after pacemaker
placement

Difference in
echocardiographic
data

p

EF (%)

58.0 ± 11.5

54.8 ± 15.8

−3.2 ± 12.8

.137 (W)

Tricuspid Regurgitation Score

2.8 ± 1.5

2.7 ± 1.4

−0.2 ± 1.1

.383 (T)

TAPSE (cm)

1.9 ± 0.4

1.9 ± 0.5

0.0 ± 0.4

.896 (T)

IVC dilation (cm)

2.3 ± 0.5

2.3 ± 0.5

0.0 ± 0.7

1.000 (W)

RVD (cm)

3.1 ± 1.0

3.0 ± 0.7

−0.1 ± 0.9

.738 (T)

RVSP (mmHg)

39.8 ± 12.5

36.9 ± 14.0

−2.9 ± 12.8

.189 (T)

RA area (cm2)

18.8 ± 11.2

18.5 ± 10.8

−0.3 ± 10.5

.625 (W)

T A B L E 4 Echocardiographic changes
from before TAVR to 2 years after
permanent pacemaker implantation for
valve size < 29 mm in diameter

Abbreviations: EF, ejection fraction; IVC, inferior vena cava; RA, right atrium RVD, right ventricular
diameter; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion;
TAVR, transcatheter aortic valve replacement; (T), paired t‐test; (W), Wilcoxon signed‐rank test.

Difference in
echocardiographic
data

Variables

Baseline
echo
pre‐TAVR

Echocardiogram
after pacemaker
placement

EF (%)

49.3 ± 14.7

50.3 ± 12.4

1.0 ± 10.2

.560 (T)

Tricuspid Regurgitation Score

2.1 ± 1.4

2.3 ± 1.1

0.2 ± 1.4

.400 (T)

TAPSE (cm)

2.0 ± 0.4

2.0 ± 0.4

0.0 ± 0.4

.837 (T)

IVC dilation (cm)

2.3 ± 0.4

2.3 ± 0.5

0.0 ± 0.5

1.000 (W)

RVD (cm)

3.3 ± 0.9

3.7 ± 0.8

0.3 ± 1.1

.220 (T)

37.3 ± 12.2

30.1 ± 14.6

−7.1 ± 15.7

.024 (T)

14.4 ± 4.3

16.9 ± 6.0

2.5 ± 4.3

.176 (T)

RVSP (mmHg)
2

RA area (cm )

T A B L E 5 Echocardiographic changes
from before TAVR to 2 years after
permanent pacemaker implantation for
valve size ≥ 29 mm in diameter

p

Abbreviations: EF, ejection fraction; IVC, inferior vena cava; RA, right atrium RVD, right ventricular
diameter; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion;
TAVR, transcatheter aortic valve replacement; (T), paired t‐test; (W), Wilcoxon signed‐rank test.

TABLE 6

Tricuspid Regurgitation Score Difference from before TAVR to 2 years after PPM
TR Score Difference 0

TR Score Difference 1

TR Score Difference 2

TR Score Difference 3

TR Score Difference 4

Valve size < 29 mm (44)

33 (75%)

9 (20%)

2 (5%)

0 (0%)

0 (0%)

Valve size ≥ 29 mm (38)

24 (63%)

8 (21%)

5 (13%)

0 (0%)

1 (3%)

Note: TR Score Difference calculated using pre‐TAVR TR score subtracted from post‐TAVR TR score.
Abbreviations: TAVR, transcatheter aortic valve replacement; TR, tricuspid regurgitation.
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Paul Nona

This is a single‐center retrospective study with a small sample size
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of patients. This study is unable to elucidate if patients with pre‐
TAVR imaging would have had worsening tricuspid regurgitation
as a progression of their natural pathophysiological disease, as a
result of larger TAVR device implantation, or if pacemaker implantation accelerated the process. This study is additionally
unable to differentiate if the worsening tricuspid regurgitation
mechanistically was caused by pacer wire impingement on focal
leaflets, versus tricuspid annular dilatation, tricuspid annulus deformation due to TAVR device, or presence of underlying disease
states such as atrial fibrillation. Mechanistically, this study has
demonstrated that tricuspid regurgitation, TAVR device, and
pacemaker implantation is a more complex anatomical interaction
than previously appreciated and 2‐year follow‐up echocardiographic information may not be sufficient to extrapolate long‐term
right heart function conclusions for this patient population.
Prospective studies with larger sample size and longer follow‐up
are needed to gain more insight.

6

| C O N CL U S I O N

Tricuspid regurgitation is a clinically significant and undertreated
disease. Defining the etiology and anatomical pathophysiology of
tricuspid regurgitation is a work in progress. In this study, we have
demonstrated a patient population that may be predisposed to developing worsening tricuspid regurgitation and right heart function
after TAVR and pacemaker implantation. Given the recent advances
in transcatheter‐based valvular therapies, larger studies with long‐
term follow‐up are necessary to prospectively study the interactions
of TAVR devices, pacemaker implantation, and right heart function
for clarity on optimal intervention strategies.17
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